Elanco Animal Health Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELAN research report →
Range $24 – $30
Price Chart
About the company
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro.
- CEO
- Jeffrey N. Simmons
- IPO
- 2018
- Employees
- 9,650
- HQ
- Indianapolis, IN, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend, holding above both the 50-day and 200-day moving averages. It sits near the upper end of its 52-week range, with the setup still favoring a trend continuation rather than a deep reset.
Street sentiment is constructive, with a Buy consensus and an average target of 26.67 versus a 24.00 low and 30.00 high. Recent changes are mixed but not deteriorating: KeyBanc stayed Overweight, while Jefferies cut to Hold and Goldman Sachs moved from Sell to Buy.
The earnings profile is strong, with 7 of the last 8 quarters beating estimates and the most recent quarter topping by 35.0%. Next-year EPS is still modeled higher at 1.2927, so shareholders should watch whether revenue growth and margin discipline keep supporting another beat-and-raise pattern.
No meaningful discretionary insider buying or selling stands out. The only clear sale was 4,350 shares by an officer on 2026-10-15, while the rest of the activity is dominated by award grants and routine officer/director equity issuances, which are not a bearish signal on their own.
Profitability is improving but still uneven, with gross margin at 56.2% and operating margin at 7.71% against a net margin of -2.86%. Revenue grew 11.3% year over year, and free cash flow was $836 million in fiscal 2025, but leverage remains heavy with $4.02 billion of debt versus $545 million of cash.
ELAN trades as a specialty animal-health name with steadier cash generation than many cyclicals, but its balance sheet remains a key differentiator to monitor. Valuation is not stretched versus the group, with a 24.26 P/E and a consensus target above the current share price.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.87B
- P/E
- -89.00
- Fwd P/E
- 21.93
- PEG
- 0.09
- P/S
- 2.59
- P/B
- 2.01
- EV/EBITDA
- 24.43
- Div Yield
- 0.00%
- Gross Margin
- 53.48%
- Op Margin
- 10.02%
- Net Margin
- -2.86%
- ROE
- -2.24%
- ROIC
- 4.44%
Latest fiscal year · YoY change
- Revenue
- $4.71B+6.2%
- Gross Profit
- $2.05B+7.4%
- Op Income
- $252.00M
- Net Income
- $-232,000,000-168.6%
- EPS
- $-0.47-169.1%
- OCF Growth
- +3.5%
- FCF Growth
- -27.9%
- 52W High
- $27.98
- 52W Low
- $19.40
- 50D MA
- $23.58
- 200D MA
- $23.89
- Beta
- 1.72
- RSI (14)
- 56
- Avg Volume
- 5.30M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Elanco beat Q3 expectations on 11% reported revenue growth, 300 bps gross margin expansion, and strong innovation-driven pet health momentum, while raising full-year guidance and reasserting its 2027 growth algorithm.· November 6, 2026
- Q3 revenue was $1.265 billion, up 11% reported and 9% organic constant currency; adjusted EBITDA was $243 million, up 23%, and adjusted EPS was $0.27, up 42%.
- Adjusted gross margin expanded to 56.1%, up 300 basis points, helped by price, mix, and productivity efforts, and free cash flow reached $362 million.
- Innovation remained the growth engine: innovation revenue was $328 million, up 40% year over year, led by Zenrelia and Credelio Quattro.
- Management raised full-year 2026 guidance across revenue, EBITDA, EPS, and innovation revenue, and said it is already focused on 2027.
- The company said net leverage fell to 2.9x after $216 million of debt reduction in the quarter, crossing its sub-3.0x milestone.
Elanco reported third-quarter revenue of $1.265 billion, up 11% on a reported basis and 9% in organic constant currency. Adjusted gross margin was 56.1%, up 300 basis points year over year; adjusted EBITDA was $243 million, up $45 million or 23%; and adjusted EPS was $0.27, up 42%. Innovation revenue was $328 million, up 40% year over year. For full-year 2026, management raised organic constant-currency revenue growth to approximately 8% from 6% to 7%, with reported revenue of $5.155 billion to $5.180 billion. Adjusted EBITDA guidance increased by about $35 million, adjusted EPS guidance was raised by $0.06 at the midpoint to $1.17 to $1.20, and innovation revenue target was raised to $1.275 billion. For Q4, Elanco expects revenue of $1.190 billion to $1.215 billion, organic constant-currency growth of 4% to 6%, adjusted EBITDA of $185 million to $200 million, and adjusted EPS of $0.16 to $0.19.
Jeffrey Simmons framed the quarter as evidence that Elanco’s “growth, innovation, cash” strategy is working, emphasizing share gains, price realization, and durable demand for differentiated products. He repeatedly said the company is winning on “best medicine,” not discounting, and argued that temporary competitive promotions are not changing the longer-term trajectory. He also highlighted strong momentum in Zenrelia, Quattro, and Befrena, plus a broad innovation pipeline that supports growth into 2027 and beyond.
Robert VanHimbergen focused on the financial translation of the operating momentum: 11% revenue growth, 56.1% gross margin, $243 million of adjusted EBITDA, and $0.27 adjusted EPS. He attributed margin improvement to pricing, favorable mix, and Elanco Ascend productivity actions, noting that higher inventory costs discussed in prior quarters are now behind the company. He also pointed to $216 million of debt reduction in the quarter, $317 million year to date, free cash flow of $362 million at quarter end, and net leverage of 2.9x; he said the company is ahead of pace toward $1 billion of cumulative free cash flow by 2028 and expects continued margin improvement through 2027.
Analysts focused on gross margin sustainability, Costco’s non-renewal, competition in pet health, the pace of Zenrelia and Quattro share gains, and the outlook for 2027. Management said Q3 margin strength came from price, mix, and Ascend, and that it expects continued multi-year gross margin and EBITDA improvement, though Q4 pricing should be closer to a 2% to 3% historical rate. On Costco, management said the impact is mostly a Q1 issue in 2027 and will be offset by other retail distribution wins; on competition, they said they are seeing targeted, time-bound promotions but no change in share trajectory or unusual stocking. On Zenrelia and Befrena, management said Zenrelia continues to gain first-line use and clinic penetration, while Befrena is moving from phased launch to full launch in Q1 and should be additive, especially in corporate accounts.
The call presented a clear bull case built around innovation-led share gains, especially in pet health, where Zenrelia and Quattro continue to take share and support price. Management sounded confident that Elanco has room to keep growing through new distribution, global expansion, and a pipeline it says is stronger and more advanced than before, with 5 to 6 blockbuster potential innovations expected through 2031. The balance sheet also improved meaningfully, with leverage below 3.0x and cash flow ahead of plan.
Management acknowledged several risks and headwinds, including tougher comparisons in farm animal, a Costco non-renewal that will pressure Q1 2027, and ongoing competitive promotions in pet health. Befrena is still in ramp-up and will be dilutive to margins at first, while management also flagged a gross margin headwind from significant but dilutive ProFenta volume growth and persistent inflation pressure in 2027. The company also said some farm categories can remain volatile quarter to quarter due to cycles, weather, and seasonality.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 499.83M
- Float Shares
- 494.72M
of shares held by institutions
541 13F filers
Buy/sell ratio 9.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ELAN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
| Val HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 22, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 5, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 27, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 26, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 5, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 22, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 22, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 23, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 12, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 4, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 3, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 66.54M | ▲ 9.59M |
| Dodge & Cox | 61.43M | ▼ 5.97M |
| Blackrock, Inc. | 49.28M | ▲ 426.66K |
| Vanguard Group Inc | 48.06M | ▼ 526.98K |
| Primecap Management Co | 45.44M | ▼ 5.34K |
| T. Rowe Price Investment Management, Inc. | 28.75M | ▼ 5.88M |
| Dimensional Fund Advisors LP | 25.07M | ▼ 347.29K |
| Vanguard Portfolio Management LLC | 23.09M | ▲ 416.20K |
| Vanguard Capital Management LLC | 22.54M | ▼ 64.38K |
| State Street Corp | 16.29M | ▲ 222.21K |
| Black Creek Investment Management Inc. | 13.39M | ▲ 346.00K |
| Marshall Wace, Llp | 10.02M | ▲ 5.59M |
Held by 528 ETFs
Biggest fund positions in ELAN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Modi Rajeev A. | other | 55.151 |
| Nov 13, 26 | Simmons Jeffrey N | other | 105.561 |
| Nov 13, 26 | VanHimbergen Robert M | other | 7.357 |
| Nov 3, 26 | Preston Jamie | other | 0 |
| Oct 30, 26 | Modi Rajeev A. | other | 64.047 |
| Oct 30, 26 | VanHimbergen Robert M | other | 8.544 |
| Oct 30, 26 | Simmons Jeffrey N | other | 122.59 |
| Oct 16, 26 | Modi Rajeev A. | other | 62.715 |
| Oct 16, 26 | Simmons Jeffrey N | other | 120.04 |
| Oct 16, 26 | VanHimbergen Robert M | other | 8.366 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELAN coverage
Recent articles, reports, and earnings notes.

Elanco Animal Health (ELAN): Turnaround Gains, Debt Still Bites
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with stronger pet-health growth, improving margins, and raised EPS guidance. The stock still screens as a Hold because leverage remains elevated and valuation leaves less room for execution missteps.

Elanco’s high-volume selloff says the turnaround was already priced in
ELAN’s 8.6% post-earnings drop on 2.8x relative volume looks less like a fresh opportunity than a market warning. The turnaround is real, but the stock is not yet earning a rerating.

Elanco Animal Health (ELAN): Growth Recovery Meets Leverage Risk
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with 2026 guidance rising and organic growth improving across pet and farm animal lines. The stock still carries meaningful balance-sheet risk, so the upside case depends on execution and debt reduction.
Want a deeper read on ELAN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
ADUS or ELAN: Which Is the Better Value Stock Right Now?
zacks.com · Nov 20
Elanco Announces Inaugural $600 Million Share Repurchase Authorization
prnewswire.com · Nov 19
Danske Bank A S Sells 117,478 Shares of Elanco Animal Health Incorporated $ELAN
defenseworld.net · Nov 19
Elanco to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 18
Elanco Animal Health Incorporated (ELAN) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Elanco Animal Health: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 9
Elanco Animal Health Q3 Earnings Call Highlights
marketbeat.com · Nov 7
Elanco Animal Health Incorporated (ELAN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice